Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00915083 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

Start date: June 1, 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics of the amrubicin and if it has an effect on the heart.

NCT ID: NCT00909402 Completed - Stomach Neoplasms Clinical Trials

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric, gastroesophageal or esophageal adenocarcinomas.

NCT ID: NCT00908869 Completed - Advanced Neoplasm Clinical Trials

Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm

METRO1
Start date: May 2006
Phase: Phase 1
Study type: Interventional

Purpose: This phase I trial estimates the antiangiogenic and antivascular effect of 4 different levels of continuous low doses of the combination of Vinorelbine, Cyclophosphamide and Interferon alpha 2b (" metronomic chemotherapy ")in adult advanced neoplasm. This study is non randomized, monocentric, and with a pharmacodynamic part. Primary objective: Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b. Secondary objectives: Estimation of the antiangiogenic and/or antivascular effect (VEGF measurement) in radiography (DEC-MRI), biology and immunohistochemistry of the treatment.

NCT ID: NCT00907738 Completed - Advanced Cancer Clinical Trials

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

NCT ID: NCT00906698 Completed - Neoplasms Clinical Trials

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Start date: June 2009
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine

NCT ID: NCT00904787 Completed - Clinical trials for Relapsed or Refractory Hematological Malignancies

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Start date: April 2009
Phase: Phase 1
Study type: Interventional

To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies

NCT ID: NCT00903708 Completed - Advanced Cancers Clinical Trials

LY2275796 in Advanced Cancer

Start date: September 2006
Phase: Phase 1
Study type: Interventional

Primary Objective: - To determine a recommended Phase 2 dose of LY2275796 that may be safely administered to patients with advanced cancer, with prospects for therapeutic biologic effects. This will require simultaneous: - monitoring of toxicities & determination of maximal tolerated dose (MTD) - detecting eIF-4E target inhibition in tumor - pharmacokinetic measurements Secondary Objectives: - To estimate pharmacokinetic parameters of LY2275796 and explore pharmacokinetic/pharmacodynamic relationships - To document any antitumor activity observed with LY2275796

NCT ID: NCT00900627 Completed - Breast Cancer Clinical Trials

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

THYME
Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer. This study will be conducted in 2 parts: the first part (phase I) will determine a dose of AZD8931 that can be safely administered with paclitaxel chemotherapy. The second part (phase II) will determine the efficacy and safety of AZD8931 in combination with paclitaxel chemotherapy in breast cancer.

NCT ID: NCT00900614 Completed - Prostatic Neoplasms Clinical Trials

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.

NCT ID: NCT00900406 Completed - Breast Cancer Clinical Trials

Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Start date: January 2007
Phase: N/A
Study type: Observational

RATIONALE: Collecting and storing samples of blood, urine, and tissue from patients undergoing a donor stem cell transplant to test in the laboratory may help the study of graft-versus-host disease in the future. PURPOSE: This research study is collecting and storing tissue and DNA samples from patients undergoing a donor stem cell transplant.